Fintel reports that on February 24, 2025, JP Morgan upgraded their outlook for bluebird bio (NasdaqGS:BLUE) from Underweight to Neutral. Analyst Price Forecast Suggests 807.14% Upside As of ...

bluebird bio (NASDAQ:BLUE) traded lower for the fourth straight session as Bank of America and J.P. Morgan downgraded the gene therapy developer after its Q3 2024 results fell short of ...

Fintel reports that on February 24, 2025, JP Morgan upgraded their outlook for bluebird bio (LSE:0HOH) from Underweight to Neutral. As of January 28, 2025, the average one-year price target for ...